Alkem Laboratories stock
ALKEM.NSNSEAlkem Laboratories Limited, HealthcareISIN INE540L01014
65Score 65 out of 100, Neutral
Price and trend
59 / 100
Price history
−8.1% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 2.2% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 74).
The price is 10.0% below its 52-week high. Largest decline in 11 years: 28% (September 2024 to February 2025).
Chart figures for advanced users
- SMA 50$55.36
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$57.62
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$52.58
- The lowest closing price of the last twelve months.
- Resistance$62.60
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alkem Laboratories Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $6.74B, is number 36 of 77 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.56B (up 14.9% year on year) and earnings of $244.65M (up 6.3%).
- For fiscal 2027, analysts expect on average revenue of $1.77B (up 13.4%) and adjusted earnings per share of $2.06 (up 0.4%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 208 of 702 in Healthcare, median 53.
- The P/E is 29.4 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 27.5).
- Our model puts fair value at $49.40, with the price 14% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 69
- More cash than debtCash $432.08M, financial debt $217.59M.Stability 94
- High return on capitalReturn on invested capital 19.2% in fiscal 2026, Drug Manufacturers (Specialty & Generic) median 11.3%.Profitability 79
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and profitability, while growth and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $41.16 and expensive above $61.75 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $36.39 (cash-flow model) and $62.41 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $46.50, at 11.6% it would be $53.54.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 13.4% on the twelve months before. Revenue has grown strongly since 2010, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 65%, operating 18%, net 16%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 5 Feb 2027in 84 days
- Last reported
- 13 Aug 2026EPS reported $0.46 (expected $0.50)below expectations
Analyst estimates
Earnings estimates have barely changed since 28 Oct 2026.
- Earnings per share
- $2.060.0%
- Revenue
- $1.77B0.0%
- Earnings per share
- $2.400.0%
- Revenue
- $1.97B0.0%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Alkem Laboratories
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Glenmark PharmaceuticalsGLENMARK.NS $7.98B74
- AlkermesALKS $7.89B53
- Amneal PharmaceuticalsAMRX $7.56B58
- Huadong Medicine000963.SZ $6.9B60
- Lantheus HoldingsLNTH $6.62B76
- China Resources Sanjiu Medical & Pharmaceutical000999.SZ $6.25B73
- Apotex HealthAPTX.TO $6.17B68
- Gland PharmaGLAND.NS $5.8B70
ETFs that hold Alkem Laboratories
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.16% | 0.65% | €4.98B |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.08% | 0.60% | €31.52M |
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.05% | 0.25% | €661.06M |
Show 5 more
| iShares MSCI EM Asia UCITS ETFCEBL | 0.03% | 0.20% | €7.14B |
| Amundi Core MSCI Emerging Markets UCITS ETF EUR DistAEMD | 0.02% | 0.18% | €9.52B |
| iShares MSCI EM UCITS ETF USD (Dist)IQQE | 0.02% | 0.18% | €8.51B |
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.02% | 0.18% | €5.26B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.02% | 0.18% | €37.98B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.